Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
Mallinckrodt
Medtronic
Boehringer Ingelheim
Daiichi Sankyo

Generated: July 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,925,231

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,925,231 protect, and when does it expire?

Patent 9,925,231 protects TRULANCE and is included in one NDA.

This patent has sixteen patent family members in seven countries.

Summary for Patent: 9,925,231
Title:Formulations of guanylate cyclase C agonists and methods of use
Abstract: The invention provides low-dose formulations of guanylate cyclase-C ("GCC") agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
Inventor(s): Comiskey; Stephen (Doylestown, PA), Feng; Rong (Langhorne, PA), Foss; John (Doylestown, PA), Shailubhai; Kunwar (Audubon, PA)
Assignee: SYNERGY PHARMACEUTICALS, INC. (New York, NY)
Application Number:15/467,631
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,925,231
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,925,231

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Salix TRULANCE plecanatide TABLET;ORAL 208745-001 Jan 19, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,925,231

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011302006 ➤ Sign Up
Australia 2013232306 ➤ Sign Up
Australia 2016216716 ➤ Sign Up
Australia 2018286626 ➤ Sign Up
Canada 2810243 ➤ Sign Up
Canada 2867292 ➤ Sign Up
Eurasian Patent Organization 201491697 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Merck
AstraZeneca
Cipla
Julphar
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.